These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 29228697)

  • 1. EGFR mutation, smoking, and gender in advanced lung adenocarcinoma.
    Tseng CH; Chiang CJ; Tseng JS; Yang TY; Hsu KH; Chen KC; Wang CL; Chen CY; Yen SH; Tsai CM; Huang MS; Ho CC; Yu CJ; Tsai YH; Chen JS; Chou TY; Tsai MH; Chen HY; Su KY; Chen JJW; Chen HW; Yu SL; Liu TW; Chang GC
    Oncotarget; 2017 Nov; 8(58):98384-98393. PubMed ID: 29228697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation.
    Erdogan B; Kodaz H; Karabulut S; Cinkaya A; Tozkir H; Tanriverdi O; Cabuk D; Hacioglu MB; Turkmen E; Hacibekiroglu I; Uzunoglu S; Cicin I
    Bosn J Basic Med Sci; 2016 Nov; 16(4):280-285. PubMed ID: 27371767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study.
    Kim IA; Lee JS; Kim HJ; Kim WS; Lee KY
    BMC Cancer; 2018 Jul; 18(1):768. PubMed ID: 30055587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in males, smokers, and non-adenocarcinoma lung cancer in patients with EGFR mutations.
    Zeng Z; Chen HJ; Yan HH; Yang JJ; Zhang XC; Wu YL
    Int J Biol Markers; 2013 Sep; 28(3):249-58. PubMed ID: 23873621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic role of epidermal growth factor receptor mutation status in patients with de novo lung adenocarcinoma.
    Li B; Ren X; Guo H; Guo Y; Han F; Wen X; Wu J; Li X; Ren Y; Hu X; Liu Z
    Transl Cancer Res; 2021 Mar; 10(3):1549-1558. PubMed ID: 35116479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
    Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
    Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment.
    Chung KP; Huang YT; Chang YL; Yu CJ; Yang CH; Chang YC; Shih JY; Yang PC
    Chest; 2012 Feb; 141(2):420-428. PubMed ID: 21799026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
    Cha YK; Lee HY; Ahn MJ; Park K; Ahn JS; Sun JM; Choi YL; Lee KS
    J Thorac Dis; 2016 Nov; 8(11):3175-3186. PubMed ID: 28066597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Jain A; Lim C; Gan EM; Ng DZ; Ng QS; Ang MK; Takano A; Chan KS; Tan WM; Kanesvaran R; Toh CK; Loo CM; Hsu AA; Devanand A; Lim CH; Koong HN; Koh T; Fong KW; Yap SP; Kim SW; Chowbay B; Oon L; Lim KH; Lim WT; Tan EH; Tan DS
    PLoS One; 2015; 10(5):e0123587. PubMed ID: 25955322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divergent epidermal growth factor receptor mutation patterns between smokers and non-smokers with lung adenocarcinoma.
    Tseng JS; Wang CL; Yang TY; Chen CY; Yang CT; Chen KC; Hsu KH; Tsai CR; Chang GC
    Lung Cancer; 2015 Dec; 90(3):472-6. PubMed ID: 26474957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
    Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
    Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma.
    Cho JH; Jung HA; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
    J Cancer Res Clin Oncol; 2019 May; 145(5):1341-1349. PubMed ID: 30900155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis].
    Chen L; Fu M; Zhou J; Yao Y; Zhou J
    Zhongguo Fei Ai Za Zhi; 2019 May; 22(5):312-318. PubMed ID: 31109441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma.
    Tanaka K; Hida T; Oya Y; Oguri T; Yoshida T; Shimizu J; Horio Y; Hata A; Kaji R; Fujita S; Sekido Y; Kodaira T; Kokubo M; Katakami N; Yatabe Y
    J Thorac Oncol; 2015 Dec; 10(12):1720-5. PubMed ID: 26743855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma.
    Riudavets M; Bosch-Barrera J; Cabezón-Gutiérrez L; Diz Taín P; Hernández A; Alonso M; Blanco R; Gálvez E; Insa A; Mielgo X; Morán T; Ponce S; Roa D; Sánchez JM; Majem M
    Clin Transl Oncol; 2021 Dec; 23(12):2560-2567. PubMed ID: 34292495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic analysis of patients with mutant and wild-type
    Zheng H; Zhang Y; Zhan Y; Liu S; Lu J; Feng J; Wu X; Wen Q; Fan S
    Cancer Manag Res; 2019; 11():6139-6150. PubMed ID: 31308750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
    Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
    Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma.
    Matsumura Y; Suzuki H; Ohira T; Shiono S; Abe J; Sagawa M; Sakurada A; Katahira M; Machida Y; Takahashi S; Okada Y
    Lung Cancer; 2017 Dec; 114():23-30. PubMed ID: 29173761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.